Evaluation of efficacy and safety of Cerebrolysin as add-on therapy in patients with acute stroke after failed recanalisation therapy

Efficacy of Cerebrolysin treatment as an add-on therapy to thrombolysis and thrombectomy in severe stroke patients with unsuccessful reperfusion - a prospective single-center clinical study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15233803

Enrollment

Registered

2020-05-25

Start date

2018-01-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke Circulatory System Stroke, not specified as haemorrhage or infarction

Interventions

The study group are 20 patients with acute moderate and severe ischemic stroke, treated in University Hospital Centre Zagreb with either thrombolytic therapy alone, or thrombolysis and thrombectomy, w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 and over 2. Patients with acute ischemic stroke and initial NIHSS 8 or more 3. Treated in University Hospital Centre Zagreb with either thrombolytic therapy alone, or thrombolysis and thrombectomy, either proven by neuroimaging methods (MRI, MRA, DSA) or clinically (no change in NIHSS in the first 12 hours after recanalisation procedure) to fulfil the criteria of unsuccessful reperfusion

Exclusion criteria

Exclusion criteria: 1. Haemorrhagic transition of a stroke on control CT scan after reperfusion therapy 2. Patients taking MAO inhibitors 3. Patients known to be allergic to the drug 4. Patients taking part in another trial

Design outcomes

Primary

Measure	Time frame
Clinical outcome measured by modified Rankin Scale (mRS) after 12 months	—

Secondary

Measure	Time frame
1. Percentage of patients with haemorrhagic transformation assessed by control neuroimaging (brain CT and/or MRI) in 24 hours and 7 days interval since symptom onset 2. Mortality rate assessed by modified Rankin Scale (mRS) at any point during study follow-up (12 months) 3. Adverse events assessed by routine laboratory or clinical changes during treatment period with Cerebrolysin	—

Countries

Croatia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026